Medical Oncologist
Cholangiocarcinoma
Intrahepatic · Perihilar · Distal · Staging · Surgery · Molecular Testing
Cholangiocarcinoma is a malignancy arising from the bile ducts—a network of small and larger ducts inside and outside the liver that carry bile. It is not, however, a single disease entity. The precise location of the tumour—within the liver, at the liver hilum or lower down in the common bile duct—has an important bearing on diagnosis, resectability and treatment planning. In advanced disease, molecular profiling has become particularly important, as it may identify additional treatment options in selected subgroups of patients.
The First Step Is to Establish the Exact Location of the Tumour
Intrahepatic Cholangiocarcinoma
Arises from the bile ducts within the liver and often presents as a liver mass.
Perihilar Cholangiocarcinoma
Arises where the right and left hepatic ducts converge. It commonly presents with biliary obstruction and jaundice.
Distal Cholangiocarcinoma
Located lower in the extrahepatic bile duct, close to the pancreas and duodenum.
How Is Cholangiocarcinoma Diagnosed and Staged?
The diagnostic work-up does not rely on a single investigation. The location and extent of the tumour, its relationship to the bile ducts and major vessels, and the presence of nodal or distant metastases must be defined accurately; histological confirmation should be obtained where required. The precise diagnostic pathway varies according to whether the tumour is intrahepatic, perihilar or distal.
01 — CT of the Chest, Abdomen and Pelvis
Contrast-enhanced CT is a key investigation for staging cholangiocarcinoma. It enables assessment of the extent of disease, lymph nodes and possible distant metastases, as well as important anatomical relationships of the tumour.
02 — MRI and MRCP: Mapping the Biliary Tree
MRI and MRCP are particularly important in perihilar and intrahepatic cholangiocarcinoma. They can define the extent of disease along the biliary tree more accurately and identify intrahepatic lesions that may affect surgical planning. By contrast, in distal cholangiocarcinoma, MRI often adds less information when a high-quality CT is already available.
03 — The Approach to Histological Confirmation Depends on Tumour Location
In intrahepatic cholangiocarcinoma, biopsy of the liver lesion or an accessible metastatic site can establish the diagnosis and provide sufficient material for further molecular testing. Extrahepatic biliary strictures may require ERCP with cytological or histological sampling and, in selected cases, cholangioscopy or EUS. In potentially resectable perihilar cholangiocarcinoma, the biopsy approach should be agreed before the procedure by a specialist hepatobiliary team.
04 — Laboratory Tests and CA 19-9
Liver function tests, bilirubin and other laboratory parameters complement imaging. CA 19-9 may provide additional information, but it is not a diagnostic test on its own. It should be interpreted with particular caution in patients with biliary obstruction and jaundice, as cholestasis can substantially elevate the level.
The Sequence of Investigations Matters
Wherever possible, complete high-quality imaging should be performed before stent placement or any other biliary intervention. Drainage may lead to inflammatory and other changes that make it more difficult to assess the true extent of the tumour accurately. This is particularly important in perihilar cholangiocarcinoma, where even the choice of which part of the liver to drain may be relevant to subsequent surgical planning.
Can the Tumour Be Removed Surgically?
Resectability is not determined by tumour size alone. Assessment includes its precise anatomical location and extent, its relationship to major vessels and the bile ducts, the presence of nodal or metastatic disease and—when liver resection is required—the volume of functional liver that will remain after surgery. The decision requires specialist multidisciplinary assessment.
Resectability May Need to Be Reassessed
In complex or borderline cases, particularly perihilar cholangiocarcinoma, assessment by a specialist hepatobiliary team may alter the evaluation of whether complete surgical resection is feasible. For this reason, specialist reassessment may be valuable before a final decision is made that a tumour is unresectable.
Intrahepatic Cholangiocarcinoma
When the disease is resectable, surgery involves removing the part of the liver containing the tumour, with the aim of complete resection.
Perihilar Cholangiocarcinoma
Surgery is often more complex because of the tumour’s location at the central bile ducts and requires careful preoperative planning.
Distal Cholangiocarcinoma
When the disease is resectable, the surgical approach differs from the other forms and depends on the exact location and extent of the tumour.
How Is Cholangiocarcinoma Treated?
The treatment strategy depends on the location and extent of the disease, whether complete surgical resection is possible, the patient’s general condition and, in advanced disease, the tumour’s molecular characteristics. Treatment therefore needs to be individualised and discussed within a multidisciplinary team.
Resectable Disease
When complete removal of the tumour is possible, surgery is the principal potentially curative treatment. The type of operation depends on the anatomical location and extent of the cholangiocarcinoma.
Unresectable Locally Advanced Disease
When the tumour cannot initially be removed surgically, systemic treatment usually forms the basis of management. In selected patients who achieve a significant response, the possibility of surgery or another local treatment may be reassessed.
After Surgery
Following surgical resection, adjuvant chemotherapy is usually discussed to reduce the risk of recurrence. Capecitabine for approximately six months is an established adjuvant treatment option.
Advanced or Metastatic Disease
In advanced disease, treatment is mainly systemic. For many patients, cisplatin and gemcitabine combined with immunotherapy—durvalumab or pembrolizumab—is a principal first-line option. The final choice is tailored to the patient’s general condition, comorbidities and disease characteristics.
Why Does Molecular Testing Matter?
Cholangiocarcinoma is not a single biological entity. In a proportion of patients, the tumour harbours specific molecular alterations that can influence treatment selection, particularly in advanced disease. Molecular profiling of the tumour therefore now has an important role in treatment planning.
When Should It Be Performed?
In locally advanced or metastatic disease, it is helpful to have the molecular test results available early—ideally while first-line treatment is ongoing—so that they can inform the next treatment decision when needed. In most cases, testing can be performed on the biopsy material already available from the diagnostic procedure, provided that the quantity and quality of tissue are sufficient, without the need for a new biopsy.
What Are We Looking For?
Testing may identify therapeutically relevant alterations involving targets such as FGFR2, IDH1, HER2 and BRAF, as well as rarer biomarkers such as NTRK or RET. Assessment of MSI/dMMR may also provide additional information about potential treatment options.
How Can the Result Change Treatment?
Identifying a suitable molecular alteration may, in selected patients, lead to targeted treatment after initial systemic therapy or open the possibility of participation in a clinical trial. For example, targeted treatments are already approved in the European Union for previously treated cholangiocarcinoma with an FGFR2 fusion/rearrangement or a specific IDH1 mutation.
Tumour Location Provides Clues—but Does Not Replace Testing
Some molecular alterations occur more often in particular types of cholangiocarcinoma. FGFR2 and IDH1 alterations, for example, are mainly associated with intrahepatic cholangiocarcinoma, whereas HER2 alterations are more common in extrahepatic forms. However, the actual molecular profile can only be established by appropriate testing of the individual tumour.
What If There Is Jaundice or Biliary Obstruction?
Cholangiocarcinoma may obstruct the normal flow of bile, causing jaundice and impaired liver function. In some cases, biliary drainage needs to be restored both to treat symptoms and possible complications and to allow treatment planning to proceed safely.
When Is Drainage Required?
The need for drainage and the method used depend on the site of obstruction, the extent of disease, the presence of cholangitis and the overall treatment plan.
The Sequence of Interventions Matters
Particularly when surgery may be possible, appropriate imaging and discussion within a specialist team should take place before stent placement or any other biliary intervention. This is especially critical in perihilar cholangiocarcinoma.
Drainage Is Part of the Overall Treatment Plan
Where required, drainage may be performed endoscopically or using other interventional techniques, depending on the anatomy and the patient’s needs. The most appropriate method is selected in collaboration with a specialist hepatobiliary team.
Frequently Asked Questions
Scientific Sources
The information on this page is based on international clinical guidelines and contemporary evidence for the diagnosis and management of cholangiocarcinoma.
Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–140. doi:10.1016/j.annonc.2022.10.506. Vogel A, Ducreux M; ESMO Guidelines Committee. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open. 2025;10(1):104003. doi:10.1016/j.esmoop.2024.104003. Rushbrook SM, Kendall TJ, Zen Y, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2024;73(1):16–46. doi:10.1136/gutjnl-2023-330029. Oh D-Y, He AR, Bouattour M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694–704. doi:10.1016/S2468-1253(24)00095-5. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised phase 3 trial. Lancet. 2023;401(10391):1853–1865. doi:10.1016/S0140-6736(23)00727-4. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–673. doi:10.1016/S1470-2045(18)30915-X. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a randomised phase 3 study. Lancet Oncol. 2020;21(6):796–807. doi:10.1016/S1470-2045(20)30157-1. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre phase 2 study (FIGHT-202). Lancet Oncol. 2020;21(5):671–684. doi:10.1016/S1470-2045(20)30109-1.